Skip to main content
S 637 115th Congress Senate Health Government information and archives Health care costs and insurance Inflation and prices Medicare Prescription drugs

Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017

Introduced: March 15, 2017 Introduced by: Wyden, Ron Democratic · Oregon See on congress.gov
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 15, 2017
Read twice and referred to the Committee on Finance.
Mar 15, 2017
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017

This bill amends title XI (General Provisions) of the Social Security Act (SSAct) to require the public disclosure of certain information provided to the Department of Health and Human Services (HHS) by a pharmacy benefit manager (PBM) that contracts with: (1) a prescription drug plan (PDP) under Medicare or Medicare Advantage (MA), or (2) a qualified health benefits plan offered through an exchange established under the Patient Protection and Affordable Care Act. Specifically, HHS must publish on its website, with respect to each PBM, information regarding: (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies.

As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan.

The bill also amends title XVIII (Medicare) of the SSAct to modify requirements regarding enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.

What's happening now March 15, 2017

Read twice and referred to the Committee on Finance.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017. 115th Congress. Open America. https://openamerica.io/bill/115-S-637/
MLA
"S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-637/.
Bluebook (legal)
S. 637, 115th Cong. (2026), https://openamerica.io/bill/115-S-637/.
Markdown link
[S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017](https://openamerica.io/bill/115-S-637/)
Report a problem